Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Condition:   Esophageal Squamous Cell Carcinoma
Intervention:   Drug: Pembrolizumab
Sponsors:   National Taiwan University Hospital;   Merck Sharp & Dohme Corp.
Not yet recruiting

http://ift.tt/2zayUQE